Effects of a protein kinase C inhibitor on the initial development of ectopic implants in a syngeneic mouse model of endometriosis.
OBJECTIVE
To evaluate the effect of protein kinase C inhibition on surgically induced endometriosis in mice.


METHODS
Prospective, randomized study.


METHODS
Academic facility.


METHODS
Sixty adult female C57BJ6 mice.


METHODS
On day -7, oral gavage of a vehicle alone or of a protein kinase C inhibitor (100 mg/kg/day, once a day) was started and continued for 1 week in donor groups A and B, respectively. On day 0, uterine fragments from donor group A were implanted into recipient mice. Recipient mice were divided randomly into two groups: group 1 (vehicle) and group 2 (protein kinase C inhibitor). Uterine fragments from donor group B were implanted into recipient mice, and they were divided randomly into two groups: group 3 (vehicle) and group 4 (protein kinase C inhibitor). Oral gavage of a protein kinase C inhibitor (100 mg/kg/day, once a day) or vehicle was continued for 1 week.


METHODS
Presence and number of ectopic implants.


RESULTS
The number of mice that developed ectopic implants was significantly lower in groups 3 (40%) and 4 (30%) than in group 1 (100%). The number of ectopic implants was significantly lower in groups 2, 3, and 4 than in group 1.


CONCLUSIONS
Protein kinase C inhibitor use partially prevented the development of ectopic implants in a mouse model of endometriosis.
Matsuzaki
Sachiko
S
Université d'Auvergne-Clermont I, Centre d'Endoscopie et des Nouvelles Techniques Interventionnelles, Clermont-Ferrand, France. sachikoma@aol.com
Canis
Michel
M
Darcha
Claude
C
Déchelotte
Pierre J
PJ
Pouly
Jean-Luc
JL
Mage
Gérard
G
D000284:Administration, Oral; D000818:Animals; D049109:Cell Proliferation / Q000187:drug effects; D004195:Disease Models, Animal; D004715:Endometriosis / Q000201:enzymology / Q000473:pathology / Q000517:prevention & control*; D005260:Female; D007441:Intubation, Gastrointestinal; D051379:Mice; D008810:Mice, Inbred C57BL; D008833:Microcirculation / Q000187:drug effects; D010388:Pelvis; D011493:Protein Kinase C / Q000037:antagonists & inhibitors* / Q000378:metabolism; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage / Q000494:pharmacology*; D014185:Transplantation, Isogeneic; D014591:Uterine Diseases / Q000201:enzymology / Q000473:pathology / Q000517:prevention & control*; D014599:Uterus / Q000187:drug effects* / Q000201:enzymology / Q000473:pathology / Q000637:transplantation
D047428:Protein Kinase Inhibitors; D011493:Protein Kinase C